Legal & General Group
MRSN

Legal & General Group’s Mersana Therapeutics MRSN Stock Holding History

Legal & General Group’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-444
Closed -$3.82K – 3490
2025
Q1 		$3.82K Hold
444
– – ﹤0.01% 3312
2024
Q4 		$15.9K Hold
444
– – ﹤0.01% 3110
2024
Q3 		$21K Hold
444
– – ﹤0.01% 3028
2024
Q2 		$22.3K Hold
444
– – ﹤0.01% 2974
2024
Q1 		$49.7K Sell
444
-737
-62% -$73.3K ﹤0.01% 2779
2023
Q4 		$68.5K Sell
1,181
-945
-44% -$38K ﹤0.01% 2778
2023
Q3 		$67.5K Sell
2,126
-787
-27% -$37.4K ﹤0.01% 2851
2023
Q2 		$240K Buy
2,913
+1,455
+100% +$213K ﹤0.01% 2696
2023
Q1 		$150K Buy
1,458
+50
+4% +$7.02K ﹤0.01% 2672
2022
Q4 		$206K Buy
1,408
+53
+4% +$8.96K ﹤0.01% 2598
2022
Q3 		$229K Buy
1,355
+93
+7% +$15.1K ﹤0.01% 2574
2022
Q2 		$145K Buy
1,262
+250
+25% +$23.5K ﹤0.01% 2749
2022
Q1 		$101K Buy
1,012
+7
+0.7% +$818 ﹤0.01% 2864
2021
Q4 		$156K Hold
1,005
– – ﹤0.01% 2800
2021
Q3 		$236K Buy
1,005
+445
+79% +$130K ﹤0.01% 2634
2021
Q2 		$190K Buy
560
+36
+7% +$13.6K ﹤0.01% 2546
2021
Q1 		$212K Sell
524
-20
-4% -$9.7K ﹤0.01% 2445
2020
Q4 		$362K Sell
544
-4
-0.7% -$2.22K ﹤0.01% 2318
2020
Q3 		$255K Sell
548
-45
-8% -$22.7K ﹤0.01% 2319
2020
Q2 		$347K Buy
593
+404
+214% +$138K ﹤0.01% 2253
2020
Q1 		$27K Sell
189
-51
-21% -$8.91K ﹤0.01% 2801
2019
Q4 		$34K Hold
240
– – ﹤0.01% 2996
2019
Q3 		$9K Hold
240
– – ﹤0.01% 3278
2019
Q2 		$24K Buy
240
+163
+212% +$19.2K ﹤0.01% 3128
2019
Q1 		$10K Hold
77
– – ﹤0.01% 3247
2018
Q4 		$8K Hold
77
– – ﹤0.01% 3287
2018
Q3 		$19K Hold
77
– – ﹤0.01% 3221
2018
Q2 		$35K Sell
77
-1
-1% -$439 ﹤0.01% 2931
2018
Q1 		$31K Buy
78
+50
+179% +$19.7K ﹤0.01% 2965
2017
Q4 		$12K Hold
28
– – ﹤0.01% 3219
2017
Q3 		$12K Buy
+28
New +$11K ﹤0.01% 3259

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Legal & General Group's MRSN Position: Q2 2025 in Review

Legal & General Group sold out of Mersana Therapeutics (MRSN) in Q2 2025, closing a stake of 444 shares — an estimated $3.82K sold.

Legal & General Group first reported a position in MRSN in Q3 2017 and held it in 31 quarters. The position peaked at $362K in Q4 2020. 83 funds tracked by Wall St. Rank hold MRSN as of Q2 2025.

  • Legal & General Group reported no remaining Mersana Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Legal & General Group sold 444 Mersana Therapeutics shares in Q2 2025, an estimated $3.82K.
  • Legal & General Group first reported a position in Mersana Therapeutics in Q3 2017 and held it in 31 quarters.
  • Legal & General Group's Mersana Therapeutics position peaked at $362K in Q4 2020.
  • 83 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2025.

Based on Legal & General Group's 13F filing for Q2 2025, filed 12 Aug 2025.